Navigation Links
ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
Date:11/6/2007

- New Data Presented at American Heart Association Scientific Sessions 2007

-

ORLANDO, Fla., Nov. 6 /PRNewswire/ -- ARCA Discovery, a privately held biopharmaceutical company, announced today that investigators presented new data analyses on ARCA Discovery's lead product candidate bucindolol, a next-generation beta-blocker and vasodilator for heart failure, atrial fibrillation, and arrhythmia, from the Beta-blocker Evaluation of Survival Trial (BEST) at the American Heart Association's (AHA) Scientific Sessions 2007 Orlando, Florida.

"The data presented today provided us with more evidence supporting the potential of bucindolol as a targeted therapy for the treatment of heart failure," said Michael R. Bristow, M.D., Ph.D., chief science and medical officer of ARCA. "Importantly, we are encouraged by the data demonstrating bucindolol's effect in preventing atrial fibrillation and life threatening ventricular arrhythmia, showing the promise for bucindolol in additional indications. In addition, the BEST trial investigators were able to extend the observation of pharmacogenetic targeting of bucindolol to benefits on cardiovascular hospitalizations, which in effect gives the drug and targeting concept a broader application."

"Effects of Bucindolol on Cardiovascular Mortality and Morbidity Determined by the Beta-1 389 Arg/Gly Receptor Polymorphism Data from a sub-study analysis of the BEST cohort" (Presentation #901) presented by Michel White, M.D. from the Montreal Heart Institute, demonstrated for the first time that in the entire 2,708 patient cohort of BEST, chronic administration of bucindolol results in a significant reduction in cardiovascular hospitalizations, as well as in the previously reported heart failure hospitalizations and cardiovascular mortality. In addition, results were reported from the large (1,040 patient) DNA substudy of BEST, a hypothesis-driven, prospectively-designed study initiated
'/>"/>

SOURCE ARCA Discovery, Inc.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... new therapeutic option for ... rheumatoid arthritis ... that the,Arthritis Advisory Committee of the U.S. Food and Drug ... ACTEMRA(R),(tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal,antibody, for reducing the ...
... SANTA CLARA, Calif., July 29 Align,Technology, Inc. ... addition to its,Invisalign product family: Invisalign Teen for ... clear,removable aligners that meet their desire for aesthetic ... busy schedules of sports, music and,other activities. According ...
... born too soon and too small accounted for a growing ... from the National Center for Health Statistics, (NCHS). , ... of infant deaths in 2005, up from 34.6 percent in ... Linked Birth/Infant Death Data Set," Vol. 57, No. 2, of ...
... Announces Results of Milken ... Institute Study Future Costs Can Be Avoided with Proper Treatment and ... ... Institute, the annual economic impact on New,Jersey,s economy of the most common chronic diseases is ...
... for Friday, August 1, 2008 at 10 AM, ... QGP ) (http://www.QuantumMD.com ) has announced that pursuant ... Caridad Center, Palm Beach,County,s largest free clinic, last week, ... enterprise healthcare system. The screening is,scheduled to follow the ...
... The majority of general internists and pediatricians in the ... providers for young adults with complex chronic illnesses that ... national survey. , The survey, conducted by researchers at ... of Michigan, examined a random sample of internists and ...
Other Medicine News:Health News:FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis 2Health News:FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis 3Health News:FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis 4Health News:Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM) 2Health News:Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM) 3Health News:Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM) 4Health News:Preterm birth contributes to growing number of infant deaths 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 3Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 4Health News:The Quantum Group Announces Exclusive Screening of New PWeR(TM) System 2Health News:The Quantum Group Announces Exclusive Screening of New PWeR(TM) System 3Health News:Most generalists reluctant to provide primary care for young adults with chronic illness 2Health News:Most generalists reluctant to provide primary care for young adults with chronic illness 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: